Skip to main content

Jane Meisel, MD

Meisel Headshot
Interview
01/10/2025
In this interview, Jane L. Meisel, MD, discusses advancements in early breast cancer detection, the integration of standard and emerging treatments, strategies for improving patient adherence, and opportunities for optimizing care through...
In this interview, Jane L. Meisel, MD, discusses advancements in early breast cancer detection, the integration of standard and emerging treatments, strategies for improving patient adherence, and opportunities for optimizing care through...
In this interview, Jane L....
01/10/2025
Journal of Clinical Pathways
Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD
Videos
02/21/2024
In this video, our experts explore therapy options for patients with high-risk HER2-positive breast cancer, sharing their views on anthracycline-based therapies, neratinib, and immunotherapy for these patients, and discussing data from the...
In this video, our experts explore therapy options for patients with high-risk HER2-positive breast cancer, sharing their views on anthracycline-based therapies, neratinib, and immunotherapy for these patients, and discussing data from the...
In this video, our experts...
02/21/2024
Oncology
Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD
Videos
02/22/2024
In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.
In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.
In this video, a panel of...
02/22/2024
Oncology
Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD
Videos
02/21/2024
In this video, a panel of experts discuss the management of patients with stage 1, HER2-positive breast cancer, sharing data from several trials in this space, including the APT, ADEPT, and ATEMPT 2.0 trials.
In this video, a panel of experts discuss the management of patients with stage 1, HER2-positive breast cancer, sharing data from several trials in this space, including the APT, ADEPT, and ATEMPT 2.0 trials.
In this video, a panel of...
02/21/2024
Oncology